

SCHEDULE 2 - TEMPLATE												
												Date of publication: 26-June-2024
	Full Name  <i>(Art. 1.01)</i>	HCPs: City of Principal Practice HCOs: city where registered  <i>(Art. 3)</i>	Country of Principal Practice  <i>(Schedule 1)</i>	Principal Practice Address  <i>(Art. 3)</i>	Unique country identifier <i>OPTIONAL</i>  <i>(Art. 3)</i>	Donations and Grants to HCOs <i>(Art. 3.01.1.a)</i>	Contribution to costs of Events <i>(Art. 3.01.1.b &amp; 3.01.2.a)</i>			Fee for service and consultancy <i>(Art. 3.01.1.c &amp; 3.01.2.c)</i>		TOTAL <i>OPTIONAL</i>
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract	
HCPs	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up. Itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)											
	BALIEVA, Flora	Stavanger	NO	Cort Adellers gate 12, Cort Adellers gate 12		N/A	N/A			40000.00		40000.00
	BONDEVIK, Bjørn	Oslo	NO	Asperudveien 61, Asperudveien 61		N/A	N/A		11955.32			11955.32
	DALAKER, Morten	Trondheim	NO	Carl Johans gate 3, Carl Johans gate 3		N/A	N/A		16861.28			16861.28
	ENDRE, Kim	Oslo	NO	Hjorteveien 11, Hjorteveien 11		N/A	N/A			20000.00		20000.00
	GATTY, Florian	Oslo	NO	Erich Mogenssensvei 38, Erich Mogenssensvei 38		N/A	N/A		13890.45			13890.45
	HANSEN, Sonali	Stavanger	NO	Cecilie Tvedts Gate 12, Cecilie Tvedts Gate 12		N/A	N/A			10000.00		10000.00
	HELSING, Per	Asker	NO	Ertelekka 1, Ertelekka 1		N/A	N/A		13685.56			13685.56
	HENRIKSEN, Anne-Marte	Kvaleya	NO	Eidkjosvegen 55		N/A	N/A			10000.00		10000.00
	HOVLID, Una	ULSTEINVIK	NO	Bjørndalvegen 14a, Bjørndalvegen 14a		N/A	N/A		8951.50			8951.50
	KRISTIANSEN, Frode	Arendal	NO	Langbryggen 19 C, Langbryggen 19 C		N/A	N/A		26698.86			26698.86
	LILLEG, Mila	Oslo	NO	Borgenveien 2A, Borgenveien 2A		N/A	N/A		13685.56			13685.56
	LUND-HANSEN, Kristin	ÅLESUND	NO	Åregjerdet 9A, Åregjerdet 9A		N/A	N/A		6731.82			6731.82
	MUSLIBEGOVIC, Lela	Trondheim	NO	Carl Johans gate 3, Carl Johans gate 3		N/A	N/A		16246.62			16246.62
	MØRK, Cato	Oslo	NO	Tennisveien 19, Tennisveien 19		N/A	N/A		13685.56	10000.00		23685.56
	SKOIE, Inger Marie	Tananger	NO	Sjøleik 44		N/A	N/A			10000.00		10000.00
	STANG, Henning	Drammen	NO	Nedre Storgate 13, Nedre Storgate 13		N/A	N/A		13685.56			13685.56
	TVEIT, Kåre	Bergen	NO	Grennevollen 2, Grennevollen 2		N/A	N/A		12178.58	22500.00		34678.58
	TZELLOS, Thrasylvoulos	Bode	NO	Fjellveien 2B, Fjellveien 2B		N/A	N/A			30000.00		30000.00
	VEER, Ernst	Arendal	NO	Langbryggen 19 C, Langbryggen 19 C		N/A	N/A		18209.96			18209.96
ZINK, Alexander	München	NO	Biedersteiner Str. 29		N/A	N/A		1872.44	42617.45		44489.89	
HCOs	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons											
	Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02					N/A	N/A					
	Number of Recipients in aggregate disclosure - Art. 3.02					N/A	N/A					
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02					N/A	N/A					N/A
	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up. Itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)											
OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons												
R & D	Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02											
	Number of Recipients in aggregate disclosure - Art. 3.02											
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02											N/A
AGGREGATE DISCLOSURE												
Transfers of Value re Research & Development as defined - Article 3.04 and Schedule 1												383456.52